Edaravone dexborneol versus placebo on functional outcomes in patients with acute ischaemic stroke undergoing endovascular thrombectomy (TASTE-2): randomised controlled trial.

BMJ · 2026 · PMC12776454 · PMID 41500725

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

borderline significanceno p-value reported

In this trial, edaravone dexborneol was associated with a 5.4% absolute increase in functional independence compared with placebo, reaching borderline significance.

also in 7,017 other papers

marginally significantno p-value reported

This discrepancy ultimately resulted in findings that were marginally significant, probably owing to an insufficient sample size.

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.